Claims for Patent: 9,403,799

Summary for Patent: 9,403,799

Title:	Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Abstract:	Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
Inventor(s):	Schadt; Oliver (Rodenbach, DE), Dorsch; Dieter (Ober-Ramstadt, DE), Stieber; Frank (Heidelberg, DE), Blaukat; Andree (Schriesheim, DE)
Assignee:	MERCK PATENT GMBH (Darmstadt, DE)
Application Number:	14/602,921
Patent Claims:	1. A method for treating a disease which is influenced by inhibition of Met kinase, wherein treating does not include prevention, or a method for stabilizing or improving the clinical symptoms of a disease which is influenced by inhibition of Met kinase, comprising administering to a subject having said disease a pharmaceutical composition, comprising a pharmaceutically acceptable carrier, and an active ingredient selected from the group consisting of TABLE-US-00007 No. Name "A1" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, sulfate "A2" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, mesylate "A3" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, besylate "A4" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, p-tosylate "A5" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, fumarate "A6" 6-(1-Methyl-1H-pyrazol-4-yl)-2-{3-[5- (2-morpholin-4-ylethoxy)pyrimidin- 2-yl]-benzyl}-2H-pyridazin-3-one, maleate "A7" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, hydrochloride monohydrate "A8" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, hydrobromide "A9" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, mesylate "A10" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, besylate "A11" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, malate "A12" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, fumarate "A13" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, maleate, and "A14" 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy) pyrimidin-2-yl]benzyl}-6-oxo-1,6- dihydropyridazin-3-yl)benzonitrile, p-tosylate or a tautomer or stereoisomer thereof, wherein the pharmaceutical formulation is in the form of one or more dosage units, which is provided either as a single dose per day or in a series of doses of two or more per day so that the total daily dose would be the same as for the single dose per day, and wherein said single or series of daily doses comprise 0.5 mg to 1 g of said active ingredient, or 0.1 to 100 mg of said active ingredient per kg of body weight of the intended recipient mammal. 2. A method according to claim 1, wherein the pharmaceutical composition is in the form of said single or series of daily doses and which comprise 1 mg to 700 mg of said active ingredient, or 1 to 10 mg of said active ingredient per kg of body weight of the intended recipient mammal. 3. A method according to claim 1, wherein the pharmaceutical composition is in the form of said single dose and which comprises 5 mg to 100 mg of said active ingredient. 4. A method according to claim 1, wherein the pharmaceutical composition contains 3-(1-{3-[5-(1-Methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}- -6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile, hydrochloride monohydrate. 5. A method according to claim 1, wherein said disease is a solid tumour. 6. A method according to claim 1, wherein said disease is a solid tumour which originates from the group consisting of tumors of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and the lung. 7. A method according to claim 1, wherein said disease is a solid tumour which originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma. 8. A method according to claim 1, wherein said disease is a solid tumour which originates from the group consisting of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma. 9. A method according to claim 1, wherein said disease is a tumour of the blood and immune system. 10. A method according to claim 1, wherein said disease is a tumour which originates from the group consisting of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and chronic lymphatic leukaemia. 11. A method according to claim 1, further comprising administering a pharmaceutically active compound, which is not a compound of claim 1. 12. A method according to claim 1, wherein the disease is a solid tumour which originates from the group consisting of tumors of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and the lung, or the disease is a solid tumour which originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma, or the disease is a solid tumour which originates from the group consisting of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma, or the disease is a tumour of the blood and immune system, or the disease is a tumour which originates from the group consisting of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and chronic lymphatic leukaemia. 13. A method according to claim 1, which is for treating a disease which is influenced by inhibition of Met kinase, wherein treating does not include prevention. 14. A method according to claim 13, wherein said disease is a solid tumour. 15. A method according to claim 13, wherein said disease is a solid tumour which originates from the group consisting of tumors of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and the lung. 16. A method according to claim 13, wherein said disease is a solid tumour which originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma. 17. A method according to claim 13, wherein said disease is a tumour of the blood and immune system. 18. A method according to claim 13, wherein said disease is a tumour which originates from the group consisting of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and chronic lymphatic leukaemia. 19. A method according to claim 1, which is for stabilizing or improving the clinical symptoms of a disease which is influenced by inhibition of Met kinase. 20. A method according to claim 19, wherein the disease is a solid tumour which originates from the group consisting of tumors of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and the lung, or the disease is a solid tumour which originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma, or the disease is a solid tumour which originates from the group consisting of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma, or the disease is a tumour of the blood and immune system, or the disease is a tumour which originates from the group consisting of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and chronic lymphatic leukaemia.